TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06184009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALL, High risk
Description: Intervention Description :~* Clinical and genetic factors consistent with High risk : Induction → Consolidation~  1. BM MRD \&lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~ 2. BM MRD ≥ 0.01% after Induction, \&lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~ 3. BM MRD ≥ 0.01% after Consolidation~  <!-- -->~  1. T cell ALL : Change to very high risk regimen~ 2. Pre-B ALL : IM #1 → Intensification~     1. BM MRD \&lt; 0.01% after IM #1 : Continue with \&#39;No. 2\&#39; of High risk regimen starting with DI #1~    2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~        * T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported.
Study: NCT05534243

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard neuromuscular blocker practices
Description: Usual care neuromuscular blocker in the ED

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Nurses and physicians will be engaged regarding the clinical outcome data on the importance of shorter acting neuromuscular blockers, and the objectives of the research. Education will include in-services and lectures focused on the importance of neuromuscular blocker protocols on patient outcome. The use of neuromuscular blokers will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based neuromuscular blocker protocols.
Study: NCT05438342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adoptive immune cells
Description: Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotron RF-8EX
Description: Hyperthermia for 40-50 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermotron RF-8EX
Description: Hyperthermia for 40-50 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy，checkpoint immunotherapy, targeted therapy
Description: The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy，checkpoint immunotherapy, targeted therapy
Description: The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy，checkpoint immunotherapy, targeted therapy
Description: The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines
Study: NCT04710680

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05869071

Intervention type: DEVICE
Intervention: Sensor analyzing software (own development)
Description: A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.

Intervention type: DEVICE
Intervention: Sensor analyzing software (own development)
Description: A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.

Intervention type: DEVICE
Intervention: Sensor analyzing software (own development)
Description: A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.

Intervention type: DEVICE
Intervention: Sensor analyzing software (own development)
Description: A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.

Intervention type: DEVICE
Intervention: Body plethysmograph
Description: Body plethysmograph measures specific airway resistance

Intervention type: DEVICE
Intervention: Body plethysmograph
Description: Body plethysmograph measures specific airway resistance

Intervention type: DEVICE
Intervention: Body plethysmograph
Description: Body plethysmograph measures specific airway resistance

Intervention type: DEVICE
Intervention: Body plethysmograph
Description: Body plethysmograph measures specific airway resistance
Study: NCT05581823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Extended-release oral tablets
Study: NCT04677114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine and Outpatient Parenteral Antibiotic Therapy
Description: Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine and standard of care antibiotic treatment
Description: All participants will receive treatment of OUD and the infection per usual clinical care.
Study: NCT05275465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-006
Description: Different dose levels of HH-006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Different dose levels of placebo
Study: NCT06171529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTM
Description: CTM Flow is stored in 1cc vials and is stable at room temperature and does not need to be refrigerated. CTM Flow will be supplied to and stored at the IHTSC Beltway Surgery Center. Product will be stored at room temperature without continued temperature control. All product will be kept in the Beltway Surgery Center and will not be separated from the marketed non-study CTM. Treating Surgeons will remain blinded to the treatment group, but will ensure that only the injection is billed to patients and the CTM or saline are provided at no cost. Lexie Reissaus, CCRP will track drug accountability.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo/Saline control injection
Study: NCT04762199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flt3/MerTK Inhibitor MRX-2843
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study: NCT05171114

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of joint amplitudes
Description: Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of joint amplitudes
Description: Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb
Study: NCT04391777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fourth ventricle compression technique (CV-4)
Description: The participant is in the supine position and the principal investigator is seated at the patient's head, with elbows resting on the table. The main investigator overlaps his hands with the thenar eminences, contacting the occipital bone squamous part, between the external occipital protuberance and the participant's occipito-mastoid suture. The technique begins with a maintained compression on the occipital squamous part during a deep thorax exhalation. Throughout the compression of the occipital bone and the participant's voluntary inspirations, the principal investigator feels a gradual pressure increase at the thenar eminences. The technique will be performed until reaching the still point, in which the mobility of the occipital bone, respiratory rate and muscle tone decrease, or until 5 minutes elapsed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The main investigator uses the technique contact but does not perform any type of tissue traction or compression, maintaining this contact for 5 minutes. At the end of the stipulated time, the contact is removed in a subtle way.
Study: NCT05342753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Kysse
Description: Hyaluronic Acid: Injectable gel for lip augmentation and the correction of upper perioral rhytids
Study: NCT05225025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROSE
Description: The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based intervention that has been proven to reduce cases of post-partum depression among low-income and racially and ethnically diverse women.~ROSE is administered to pregnant women in small group settings, typically in the same location that prenatal care is being provided (in this study, a hospital setting). It is divided into four 90-minute group sessions and teaches interpersonal psychotherapy-based skills that mitigate identified risk factors for PPD such as social support, stress management skills and communication.~ROSE curriculum will be implemented using groups in a continuous cycle, with patients entering into the intervention curriculum at the time of their enrollment and continuing through until all 4 total sessions have been accomplished.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Usual hospital care with no behavioral intervention
Study: NCT05186584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION
Description: Group A will receive the 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set (total 75 oscillations) for AP mobilizations at most symptomatic segment, with 10 seconds rest between sets. Most symptomatic segment is that segment of cervical spine at which patient will feel greatest pain by palpation.~For AP mobilizations, patient will lye supine and therapist will stand by his head. Therapist will make broad contact with the thumb, at the costal process of the vertebrae to be mobilized and spread fingers around adjacent neck for stability. Shoulder will be positioned above the joint being treated. Gentle oscillatory Anteroposterior pressure will be performed by the therapist's arm and trunk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAITLAND'S LATERAL MOBILIZATION
Description: Group B will receive the same sets (i.e. 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set) for lateral mobilizations at most symptomatic segment, with 10 sec rest between each set. For lateral mobilization, patient will lye supine and therapist will stand by his head. Therapist will place the anterolateral aspect 2nd metacarpophalangeal joint over the lateral aspect of transverse process of most symptomatic segment. Gentle lateral oscillations towards the asymptomatic side will be provided by the therapist.
Study: NCT01691417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Sequntial Pnumatic Compression Leg Sleeves

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Sequntial Pnumatic Compression Leg Sleeves
Study: NCT05028114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202
Description: Tricaprilin formulated as AC-1202
Study: NCT05283811

Intervention type: DEVICE
Group type: OTHER
Intervention: NEUROPACE RNS SYSTEM
Description: This device is indicated as a therapy in reducing the frequency of seizures in individuals

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EMU
Description: Patients are admitted to the Epilepsy Monitoring Unit for observation of seizure activity prior to further treatment
Study: NCT05028114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-01
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-02
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-03
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-04
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-05
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-06
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-07
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-08
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-09
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-010
Description: Tricaprilin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-P
Description: Placebo to tricaprilin formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-P
Description: Placebo to tricaprilin formulation
Study: NCT06005753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ostheosynthesis of acetabular fractures
Description: The using of plate for fixation of acetabular fractures in surgical treatment
Study: NCT05897749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brucea javanica oil emulsion injection
Description: Drug: Brucea javanica oil emulsion injection Brucea javanica oil emulsion injection: intravenous drip, 30ml each time (add 250ml sterile physiological saline),once a day, 14 consecutive days as a cycle, at least 2 cycles completed. The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The best supportive treatment
Description: The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The best supportive treatment
Description: The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
Study: NCT04455620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT151
Description: intravenous
Study: NCT05901909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Precede-Proceed Model for individuals caring for stroke home care patients
Description: Home visits will be made to 70 stroke patients identified during the implementation phase of the research, and training based on the Precede-Proceed model will be given to 70 individuals who care for these patients in the meeting room of the hospital where the research will be conducted. In the research, pre-education evaluation will be collected at the hospital before the training for the caregivers and home visits for the patients. In the second stage, the training program planned for the caregivers will be implemented in the meeting room of the hospital. After the training program reaches all of the caregivers in the determined number, the first evaluation will be made for the caregivers and the patient in the 8th week after the training is over. The third stage is the 16th week after the completion of the training, and the final evaluation will be made for the patients and caregivers.
Study: NCT05417295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inflating air into the bronchial cuff before changing position
Description: Inflating air into the bronchial cuff before or after changing position

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Inflating air into the bronchial cuff after changing position
Description: Inflating air into the bronchial cuff after changing position
Study: NCT05470244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy and Intra-venous analgesic regimen
Description: ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation along with Routine Physical Therapy and Intra-venous analgesic regimen
Description: High frequency stimulations via Transcutaneous Electrical Nerve Simulator will be applied. ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
Study: NCT04999943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC vaccine
Description: EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
Study: NCT06148103

Intervention type: DRUG
Group type: OTHER
Intervention: Patients who received Dexmedetomodine
Description: 1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).

Intervention type: DRUG
Group type: OTHER
Intervention: patients who received propofol-fentanyl
Description: Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
Study: NCT05679115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle tool
Description: Regular use of the digital Lifestyle tool
Study: NCT05707416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gallium aluminum arsenide (Ga-Al-As) semiconductor diode laser (SMARTTM PRO, LASOTRONIX, Poland)
Description: The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group B
Description: Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
Study: NCT06484296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Before the training, students in all groups will be provided to take the Pretest.~The students included in the training group will be trained on good and green health practices in the conference hall of the Faculty by expert researchers and the green transformation coordinator of the university who have a certificate of Conscious Awareness training. Three weeks after the training, all students will be given the Green Culture Scale Post-Test.
Study: NCT06122402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SECURE Care Bundle
Description: The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives including 2-octyl-cyanoacrylate tissue adhesive, CHG dressing and silicone based remover.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standart Care
Description: It is applied in routine care in the clinic. There is no standardization and no procedure for checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives. Only CHG dressing is used for central venous catheter care.
Study: NCT04124380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure
Description: Six 50 min, twice weekly video telehealth sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure
Description: Six 50 min, twice weekly video telehealth sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).
Study: NCT05232747

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Diagnostic Test
Study: NCT04484727

Intervention type: OTHER
Intervention: PEEP-step method
Description: By changing PEEP in one or two steps up and down, transpulmonary pressure and the lung P/V curve can be determined using a dedicated software collecting data on tidal-volume changes and pressure changes during the PEEP-changes from the standard monitoring equipment or ventilator.

Intervention type: OTHER
Intervention: PEEP-step method
Description: By changing PEEP in one or two steps up and down, transpulmonary pressure and the lung P/V curve can be determined using a dedicated software collecting data on tidal-volume changes and pressure changes during the PEEP-changes from the standard monitoring equipment or ventilator.
Study: NCT05009784

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline
Description: 5-min urban park video clip (Presented on a TV)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline
Description: 5-min urban park video clip (Presented on a TV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: 5-min urban park video clip (Presented on a TV)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Manipulation
Description: 20-min 2-back task (Presented on a computer)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Manipulation
Description: 20-min 2-back task (Presented on a computer)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Manipulation
Description: 20-min 2-back task (Presented on a computer)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traffic Sound
Description: Active Comparator: Traffic Sound (Played through speakers)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traffic and Masking Sound
Description: Experimental: Traffic and Masking Sound (Played through speakers)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silence
Description: No Intervention: No sound (Played through speakers)
Study: NCT04148781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine SR
Description: Fampridine-SR 10 mg twice daily for 8 weeks
Study: NCT05863468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArchSinus implantation
Description: Unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation